http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/Press+Releases/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html <div class="xn-content"> <p class="prntac"><b><i>Expansion of <person>Magnolia Meals</person> at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1182077650" idsrc="xmltag.org" >Eisai Inc.</span> today announced the expansion of its Magnolia <i>Meals at Home</i>® program to support the Alzheimer's disease and related dementias (ADRD) community through a new initiative developed in collaboration with CaringKind. Originally created to support households affected by cancer, the program now offers practical, easy-to-use nutritional resources tailored to the needs of people living with ADRD and their care partners.</p> http://www.streetinsider.com/PRNewswire/Eisai+and+CaringKind+Launch+New+Initiative+to+Address+Mealtime+and+Nutrition+Needs+for+People+Living+with+Alzheimer%27s+Disease+and+Related+Dementias/26578907.html Mon, 01 Jun 2026 07:00:00 -0400 4523 A.11820776 O.00093063 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html <div class="xn-content"> <p class="prntac"><i>Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer</i></p><p class="prntac"><i>Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell Carcinoma with Lenvatinib Plus Pembrolizumab</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai</span> announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 <span value="ACORN:5021672661" idsrc="xmltag.org" >American Society of Clinical Oncology</span> (ASCO) Annual Meeting (#ASCO26), taking place in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago, Illinois</location> from <chron>May 29 to June http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html Wed, 20 May 2026 08:08:00 -0400 4523 A.11820776 A.37819586 A.41824856 A.50216726 O.00000304 O.00093063 O.03211432 O.05105698 O.21612337 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html <div class="xn-content"> <p class="prntac"><i>Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer</i></p><p class="prntac"><i>Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell Carcinoma with Lenvatinib Plus Pembrolizumab</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai</span> announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 <span value="ACORN:5021672661" idsrc="xmltag.org" >American Society of Clinical Oncology</span> (ASCO) Annual Meeting (#ASCO26), taking place in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago, Illinois</location> from <chron>May 29 to June http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html Wed, 20 May 2026 08:08:00 -0400 4523 A.11820776 A.37819586 A.41824856 A.50216726 O.00000304 O.00093063 O.03211432 O.05105698 O.21612337 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html <div class="xn-content"> <p class="prntac"><i>Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer</i></p><p class="prntac"><i>Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell Carcinoma with Lenvatinib Plus Pembrolizumab</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai</span> announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 <span value="ACORN:5021672661" idsrc="xmltag.org" >American Society of Clinical Oncology</span> (ASCO) Annual Meeting (#ASCO26), taking place in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago, Illinois</location> from <chron>May 29 to June http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html Wed, 20 May 2026 08:08:00 -0400 4523 A.11820776 A.37819586 A.41824856 A.50216726 O.00000304 O.00093063 O.03211432 O.05105698 O.21612337 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html <div class="xn-content"> <p class="prntac"><i>Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer</i></p><p class="prntac"><i>Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell Carcinoma with Lenvatinib Plus Pembrolizumab</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai</span> announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 <span value="ACORN:5021672661" idsrc="xmltag.org" >American Society of Clinical Oncology</span> (ASCO) Annual Meeting (#ASCO26), taking place in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago, Illinois</location> from <chron>May 29 to June http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html Wed, 20 May 2026 08:08:00 -0400 4523 A.11820776 A.37819586 A.41824856 A.50216726 O.00000304 O.00093063 O.03211432 O.05105698 O.21612337 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html <div class="xn-content"> <p class="prntac"><i>Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer</i></p><p class="prntac"><i>Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell Carcinoma with Lenvatinib Plus Pembrolizumab</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.nutley" idsrc="xmltag.org" >NUTLEY, N.J.</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai</span> announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 <span value="ACORN:5021672661" idsrc="xmltag.org" >American Society of Clinical Oncology</span> (ASCO) Annual Meeting (#ASCO26), taking place in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago, Illinois</location> from <chron>May 29 to June http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26525211.html Wed, 20 May 2026 08:08:00 -0400 4523 A.11820776 A.37819586 A.41824856 A.50216726 O.00000304 O.00093063 O.03211432 O.05105698 O.21612337